Assembly Biosciences (ASMB) Rating Increased to Hold at BidaskClub

Assembly Biosciences (NASDAQ:ASMB) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Tuesday, BidAskClub reports.

A number of other equities research analysts also recently issued reports on ASMB. Zacks Investment Research downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Chardan Capital reissued a “hold” rating and issued a $30.00 price target on shares of Assembly Biosciences in a research note on Monday, April 15th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $43.00.

Shares of Assembly Biosciences stock traded up $0.45 on Tuesday, reaching $16.45. The company had a trading volume of 168,100 shares, compared to its average volume of 302,312. The company has a market capitalization of $413.66 million, a price-to-earnings ratio of -4.13 and a beta of 1.60. Assembly Biosciences has a 52-week low of $13.13 and a 52-week high of $48.91.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.01. The business had revenue of $3.89 million for the quarter, compared to the consensus estimate of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 57.57%. As a group, equities research analysts forecast that Assembly Biosciences will post -4.37 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in ASMB. BNP Paribas Arbitrage SA grew its holdings in shares of Assembly Biosciences by 87,340.0% in the first quarter. BNP Paribas Arbitrage SA now owns 4,372 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 4,367 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Assembly Biosciences by 17.0% in the fourth quarter. Legal & General Group Plc now owns 3,847 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 558 shares in the last quarter. Marshall Wace North America L.P. grew its holdings in shares of Assembly Biosciences by 191.5% in the first quarter. Marshall Wace North America L.P. now owns 4,431 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 2,911 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in shares of Assembly Biosciences by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,073 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 5,524 shares in the last quarter. Finally, Blair William & Co. IL grew its holdings in shares of Assembly Biosciences by 18.5% in the first quarter. Blair William & Co. IL now owns 10,825 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 1,687 shares in the last quarter. Hedge funds and other institutional investors own 83.74% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Story: Trading Stocks – What are percentage gainers?

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.